Movement disorders are common, and can be difficult to categorise correctly. In this article, we present the common movement disorders seen by GPs and provide an overview of their classification. Most movement disorders presenting in primary care will need referral to a neurologist for full diagnosis and management. However, essential tremor is usually managed in primary care, and being able to differentiate it from other forms of tremor, especially Parkinson's disease, as well as being familiar with its initial management, is important. For all patients, being aware of the potential impact on daily function is paramount, and adopting a multidisciplinary approach to management should always be considered.
Get full access to this article
View all access options for this article.
References
1.
AbboudH., AhmedA., & FernandezH. H. (2011). Essential tremor: choosing the right management plan for your patient. Cleveland Clinic Journal of Medicine, 78, 821–828. doi:10.3949/ccjm.78a.10178
2.
ChouK. L. (2004). Diagnosis and management of the patient with tremor. Medicine & Health Rhode Island, 87, 135–138.
3.
DeuschlG., BainP., & BrinM. (1998). Ad hoc scientific committee. Consensus statement of the Movement Disorder Society on tremor. Movement Disorders, 13, 2–23.
4.
KelsbergG., RubensteinC., & St AnnaL. (2008). FPIN's clinical inquiries. Differential diagnosis of tremor. American Family Physician, 77, 1305–1306.
LippA., SandroniP., AhlskogJ. E., FealeyR. D., KimpinskiK., IodiceV., …, ShultsC. W. (2009). Prospective differentiation of multiple system atrophy from Parkinson disease, with and without autonomic failure. Archives of Neurology, 66, 742–750. doi: 10.1001/archneurol.2009.71
7.
LouisE. D. (2001). Clinical practice. Essential tremor. New England Journal of Medicine, 345, 887–891. doi: 10.1056/NEJMcp010928
8.
MarshallV. L., ReiningerC. B., MarquardtM., PattersonJ., HadleyD. M., OertelW. H., …, GrossetD. G. (2009). Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Movement Disorders, 24, 500–508. doi: 10.1002/mds.22108
9.
MerleU., SchaeferM., FerenciP., & StremmelW. (2007). Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut, 56, 115–120. doi: 10.1136/gut.2005.087262
10.
Müller-VahlK. R., CathD. C., CavannaA. E., DehningS., PortaM., RobertsonM. M., & Visser-VandewalleV. (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. European Child & Adolescent Psychiatry, 20, 209–217. doi: 10.1007/s00787-011-0166-4
11.
QuagliatoE. M., CarelliE. F., & VianaM. A. (2010). A prospective, randomized, double-blind study comparing the efficacy and safety of type A botulinum toxins botox and prosigne in the treatment of cervical dystonia. Clinical Neuropharmacology, 16, 316–323. doi: 10.1097/WNF.0b013e3181c46f48
RoessnerV., PlessenK. J., RothenbergerA., LudolphA. G., RizzoR., SkovL., & HoekstraP. J. (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. European Child & Adolescent Psychiatry, 20, 173–196. doi: 10.1007/s00787-011-0163-7
14.
SingerC. (2012). Comprehensive treatment of Huntington disease and other choreic disorders. Cleveland Clinic Journal of Medicine, 79, S30–S34. doi: 10.3949/ccjm.79.s2a.06
ThanviB., LoN., & RobinsonT. (2007). Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgraduate Medical Journal, 83, 384–388. doi:10.1136/pgmj.2006.054759
17.
VerdellenC., Van de GriendtJ., HartmannA., & MurphyT. (2011). European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. European Child & Adolescent Psychiatry, 20, 197–207. doi: 10.1007/s00787-011-0167-3
18.
WalkerF. O. (2007). Huntington's disease. Lancet, 369, 218–228. doi: 10.1016/S0140-6736(07)60111-1
19.
YuH., & NeimatJ. S. (2008). The treatment of movement disorders by deep brain stimulation. Neurotherapeutics, 5, 26–36. doi: 10.1055/s-0031-1299783